Digbi Health, a leader in clinically proven genetics and gut-microbiome based digital care program for managing obesity and associated inflammatory digestive, skin and cardiometabolic illnesses, announced it has completed $5.4 million in Series A funding […]
Pendulum Therapeutics – a biotech company improving health through products targeting the microbiome – today announced a $54 million investment led by Meritech Capital with participation from existing investors including Sequoia Capital, True Ventures and […]
Sinopharm will launch three probiotic supplements within the immune health, bone health and iron absorption areas based on Probi’s scientifically proven probiotic strains. Zhang Jian Ge, Director Pharmaceutical & Chemical Division of Sinopharm, states: “Sinopharm […]
SINT1A is led by Helmholtz Zentrum Muenchen, and part of the international GPPAD initiative including Prof. Ezio Bonifacio and his team at the Center for Regenerative Therapies Dresden at TU Dresden. Around one in 300 […]
ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health, today announces that it has received Investigational New Drug […]
Trillions of commensal microbes live on the mucosal and epidermal surfaces of the body and it is firmly established that this microbiome affects its host’s tolerance and sensitivity of the host to a variety of […]
4D pharma plc (AIM: DDDD) (“4D” or the “Company”), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, is pleased to announce that its […]
Sandwalk BioVentures, the strategy firm specialized on microbiome technologies, has announced its collaboration with General Inception, a US-based venture studio focused on co-founding and building science-based companies from concept on. Sandwalk will lead the Microbiome […]
The Centre for Disease Control and Prevention (CDC) has declared insufficient sleep a ‘public health problem’, with more than one-third of American adults not getting enough sleep on a regular basis. Experts in gut microbiome […]
Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to advancing therapies that address the global rise of multi-drug resistant infections, announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug […]
Novozymes, the world leader in biological solutions, announced the acquisition of the microbiome R&D team and data science platform of Biota. Based in San Diego, US, Biota pioneered industrial genomics using microbiome insights, impacting the […]